The impact of the California state lockdown during the COVID‐19 pandemic on management of patients with pancreatic ductal adenocarcinoma

Abstract

AbstractBackground and ObjectivesThe SARS‐COVID‐19 pandemic significantly limited healthcare access. We sought to evaluate whether California's lockdown in March 2020 affected staging and time to treatment of pancreatic ductal adenocarcinoma (PDAC). We hypothesized that patients diagnosed after the lockdown would have longer time to treatment and higher stage at presentation.MethodsWe retrospectively identified and categorized 1294 patients presenting to five University of California healthcare systems with a new diagnosis of PDAC into “pre‐lockdown” and “post‐lockdown” groups based on timing of pathologic diagnosis.ResultsIn the 12 months pre‐lockdown, 835 patients were diagnosed with PDAC, and 459 patients in the 6 months post‐lockdown. Demographics, staging, and treatment type were similar between eras. There was a decreased male:female ratio post‐ versus pre‐lockdown (0.97 vs. 1.25; p = 0.03). Time from symptom onset to first treatment was significantly increased among females post‐lockdown (p = 0.001). However, overall time from diagnosis to first treatment was shorter in the post‐lockdown era (median 23 vs. 26 days, p < 0.001).ConclusionsThe COVID‐19 lockdown did not significantly delay initial presentation, diagnosis, or treatment of newly diagnosed PDAC patients. Time from diagnosis to first treatment was shorter post‐lockdown. Reduced healthcare utilization for minor complaints and increased telehealth utilization may have contributed.